‹ All episodes

The BioInsights Podcast

Working Together to Safely Advance Cell & Gene Therapies

September 27, 2022 Dr John Maher of King’s College London and Leucid Bio, and featuring Dr Alastair King, Dr Francisca Neethling, and Dr Andrea Bisso Season 1 Episode 16

Chapters

What are the primary safety considerations at the preclinical stage?

How do we create more predictive approaches for advanced therapies?

What will be the greatest challenges to implementing non-animal alternatives in preclinical testing?

How to modify existing platforms?

How to choose an outsourcing partner, and what is the primary role of the CRO?

Do virtual companies have special needs regarding assay and safety considerations?

How can we work together to safely advance cell and gene therapies?

The BioInsights Podcast

Working Together to Safely Advance Cell & Gene Therapies

Sep 27, 2022 Season 1 Episode 16

Dr John Maher of King’s College London and Leucid Bio, and featuring Dr Alastair King, Dr Francisca Neethling, and Dr Andrea Bisso

Drug development is a costly and time-consuming process associated with a significant attrition rate in the clinic. Safety is an important factor in this, and is a particular issue for cell and gene therapies. A panel moderated by Dr John Maher of King’s College London and Leucid Bio, and featuring Dr Alastair King, Dr Francisca Neethling, and Dr Andrea Bisso, discuss this highly topical barrier to the further clinical and commercial success of the field.

Share Episode

Share on Facebook Share on Twitter Share on LinkedIn Download

Subscribe

Apple Podcasts Spotify More

Listen on

Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +

Share Episode

Share on Facebook Share on Twitter Share on LinkedIn

Drug development is a costly and time-consuming process associated with a significant attrition rate in the clinic. Safety is an important factor in this, and is a particular issue for cell and gene therapies. A panel moderated by Dr John Maher of King’s College London and Leucid Bio, and featuring Dr Alastair King, Dr Francisca Neethling, and Dr Andrea Bisso, discuss this highly topical barrier to the further clinical and commercial success of the field.